Applications of SARS-CoV-2 serological testing: impact of test performance, sample matrices, and patient characteristics

被引:4
作者
Fung, Chun Yiu Jordan [1 ,2 ]
Scott, Mackenzie [1 ,2 ,3 ]
Lerner-Ellis, Jordan [1 ,2 ,3 ]
Taher, Jennifer [2 ,3 ,4 ]
机构
[1] Sinai Hlth, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[2] Sinai Hlth, Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[4] Sinai Hlth, Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada
关键词
SARS-CoV-2; COVID-19; serology; immunity; antibody; INTERNATIONAL STANDARD; COVID-19; ANTIBODY; INFECTION; KINETICS;
D O I
10.1080/10408363.2023.2254390
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Laboratory testing has been a key tool in managing the SARS-CoV-2 global pandemic. While rapid antigen and PCR testing has proven useful for diagnosing acute SARS-CoV-2 infections, additional testing methods are required to understand the long-term impact of SARS-CoV-2 infections on immune response. Serological testing, a well-documented laboratory practice, measures the presence of antibodies in a sample to uncover information about host immunity. Although proposed applications of serological testing for clinical use have previously been limited, current research into SARS-CoV-2 has shown growing utility for serological methods in these settings. To name a few, serological testing has been used to identify patients with past infections and long-term active disease and to monitor vaccine efficacy. Test utility and result interpretation, however, are often complicated by factors that include poor test sensitivity early in infection, lack of immune response in some individuals, overlying infection and vaccination responses, lack of standardization of antibody titers/levels between instruments, unknown titers that confer immune protection, and large between-individual biological variation following infection or vaccination. Thus, the three major components of this review will examine (1) factors that affect serological test utility: test performance, testing matrices, seroprevalence concerns and viral variants, (2) patient factors that affect serological response: timing of sampling, age, sex, body mass index, immunosuppression and vaccination, and (3) informative applications of serological testing: identifying past infection, immune surveillance to guide health practices, and examination of protective immunity. SARS-CoV-2 serological testing should be beneficial for clinical care if it is implemented appropriately. However, as with other laboratory developed tests, use of SARS-CoV-2 serology as a testing modality warrants careful consideration of testing limitations and evaluation of its clinical utility.
引用
收藏
页码:70 / 88
页数:19
相关论文
共 184 条
  • [1] Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity
    Alefishat, Eman
    Jelinek, Herbert F. F.
    Mousa, Mira
    Tay, Guan K. K.
    Alsafar, Habiba S. S.
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2022, 15 (02) : 277 - 288
  • [2] Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis
    Allotey, John
    Stallings, Elena
    Bonet, Mercedes
    Yap, Magnus
    Chatterjee, Shaunak
    Kew, Tania
    Debenham, Luke
    Llavall, Anna Clave
    Dixit, Anushka
    Zhou, Dengyi
    Balaji, Rishab
    Lee, Siang Ing
    Qiu, Xiu
    Yuan, Mingyang
    Coomar, Dyuti
    van Wely, Madelon
    van Leeuwen, Elizabeth
    Kostova, Elena
    Kunst, Heinke
    Khalil, Asma
    Tiberi, Simon
    Brizuela, Vanessa
    Broutet, Nathalie
    Kara, Edna
    Kim, Caron Rahn
    Thorson, Anna
    Oladapo, Olufemi T.
    Mofenson, Lynne
    Zamora, Javier
    Thangaratinam, Shakila
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 370
  • [3] Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
    Amirthalingam, Gayatri
    Bernal, Jamie Lopez
    Andrews, Nick J.
    Whitaker, Heather
    Gower, Charlotte
    Stowe, Julia
    Tessier, Elise
    Subbarao, Sathyavani
    Ireland, Georgina
    Baawuah, Frances
    Linley, Ezra
    Warrener, Lenesha
    O'Brien, Michelle
    Whillock, Corinne
    Moss, Paul
    Ladhani, Shamez N.
    Brown, Kevin E.
    Ramsay, Mary E.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [4] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
    Anderson, E. J.
    Rouphael, N. G.
    Widge, A. T.
    Jackson, L. A.
    Roberts, P. C.
    Makhene, M.
    Chappell, J. D.
    Denison, M. R.
    Stevens, L. J.
    Pruijssers, A. J.
    McDermott, A. B.
    Flach, B.
    Lin, B. C.
    Doria-Rose, N. A.
    O'Dell, S.
    Schmidt, S. D.
    Corbett, K. S.
    Swanson, P. A., II
    Padilla, M.
    Neuzil, K. M.
    Bennett, H.
    Leav, B.
    Makowski, M.
    Albert, J.
    Cross, K.
    Edara, V. V.
    Floyd, K.
    Suthar, M. S.
    Martinez, D. R.
    Baric, R.
    Buchanan, W.
    Luke, C. J.
    Phadke, V. K.
    Rostad, C. A.
    Ledgerwood, J. E.
    Graham, B. S.
    Beigel, J. H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) : 2427 - 2438
  • [5] Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management
    Anka, Abubakar Umar
    Tahir, Mohammed Ibrahim
    Abubakar, Sharafudeen Dahiru
    Alsabbagh, Mohamed
    Zian, Zeineb
    Hamedifar, Haleh
    Sabzevari, Araz
    Azizi, Gholamreza
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2021, 93 (04)
  • [6] [Anonymous], 2016, EJIFCC, V27, P5
  • [7] [Anonymous], 2022, EUA AUTH SER TEST PE
  • [8] [Anonymous], 2023, CONS 2030 COVID 19 V
  • [9] [Anonymous], 2023, COR DIS 2019 COVID 1
  • [10] [Anonymous], 2023, MEASL SER